Several laboratories including ours showed that vorinostat leads to increased phosphorylation of eIF2α [19,28], which is known to affect the response of cancer cells to anti-neoplastic treatments including vorinostat [19,28,39,40]. The gene discussed is EIF2A; the disease is cancer.